基于费里的纳米药物用于疾病治疗
Yuanjun Zhu1,2, Yuefeng Zhu1, Tianmiao Cao1
1Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems , State Key Laboratory of Natural and Biomimetic Drugs , School of Pharmaceutical Sciences, Peking University, Beijing, China.
Medical review (2021)
|September 19, 2023
概括
费里丁纳米,天然蛋白质结构,为纳米医学提供了一个多功能平台. 本综述探讨了它们在疾病诊断,治疗和预防中的应用,强调了它们在临床应用中的潜力.
科学领域:
- 生物技术和纳米医学
- 蛋白质工程是指蛋白质工程.
- 药物输送系统 药物输送系统
背景情况:
- 费里是一种内源蛋白质,可以自组装成24个子单元的纳米.
- 费里纳米具有用于药物封装的空洞腔和用于修改的表面部位.
- 它固有的生物相容性,低毒性,瘤向性,稳定性和成本效益使其成为一个有前途的纳米载体.
研究的目的:
- 审查基于费里的纳米医学在疾病诊断,治疗和预防中的应用.
- 为了分类药物加载方法和在费里纳米载体中使用的药物类型.
- 调查费里功能化的策略,并讨论其在成像,药物输送和疫苗开发中的作用.
主要方法:
- 基于费里的纳米医学的综合文献综述.
- 药物加载技术和治疗剂的分类.
- 分析费里表面修饰策略 (特定地点和非特定地点).
主要成果:
- 费里纳米显示出作为多功能纳米医学平台的巨大潜力.
- 可以装载各种药物,并且可以修改费里以提供有针对性的药物和提高疗效.
- 应用范围包括疾病成像,向药物输送和疫苗开发.
结论:
- 基于费里的纳米药物在诊断,治疗和预防策略方面显示出很大的前景.
- 功能化和药物加载方法是优化费里纳米载体性能的关键.
- 解决挑战对于成功临床转化费里纳米药物至关重要.
相关概念视频
01:28The Early Endosome: Endocytosis of Transferrin
Essential proteins such as insulin or low-density lipoprotein (LDL) and micronutrients such as iron enter a eukaryotic cell through receptor-mediated endocytosis. Subsequently, the early endosomes fuse with the vesicles containing such receptor-ligand complexes and play a vital role in sorting the incoming ligands and receptors. While the ligands are either degraded inside the vesicle or released into the cytosol, their receptors are returned to the plasma membrane for further rounds of...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...